Skip to main content
Top
Published in: Calcified Tissue International 1/2018

01-01-2018 | Original Research

Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation

Authors: Michelle M. McDonald, Alyson Morse, Aaron Schindeler, Kathy Mikulec, Lauren Peacock, Tegan Cheng, Justin Bobyn, Lucinda Lee, Paul A. Baldock, Peter I. Croucher, Patrick P. L. Tam, David G. Little

Published in: Calcified Tissue International | Issue 1/2018

Login to get access

Abstract

Wnt antagonist Dkk1 is a negative regulator of bone formation and Dkk1 +/ heterozygous mice display a high bone mass phenotype. Complete loss of Dkk1 function disrupts embryonic head development. Homozygous Dkk1 / mice that were heterozygous for Wnt3 loss of function mutation (termed Dkk1 KO) are viable and allowed studying the effects of homozygous inactivation of Dkk1 on bone formation. Dkk1 KO mice showed a high bone mass phenotype exceeding that of heterozygous mice as well as a high incidence of polydactyly and kinky tails. Whole body bone density was increased in the Dkk1 KO mice as shown by longitudinal dual-energy X-ray absorptiometry. MicroCT analysis of the distal femur revealed up to 3-fold increases in trabecular bone volume and up to 2-fold increases in the vertebrae, compared to wild type controls. Cortical bone was increased in both the tibiae and vertebrae, which correlated with increased strength in tibial 4-point bending and vertebral compression tests. Dynamic histomorphometry identified increased bone formation as the mechanism underlying the high bone mass phenotype in Dkk1 KO mice, with no changes in bone resorption. Mice featuring only Wnt3 heterozygosity showed no evident bone phenotype. Our findings highlight a critical role for Dkk1 in the regulation of bone formation and a gene dose-dependent response to loss of DKK1 function. Targeting Dkk1 to enhance bone formation offers therapeutic potential for osteoporosis.
Literature
1.
go back to reference Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72(3):207–214CrossRefPubMed Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72(3):207–214CrossRefPubMed
2.
go back to reference Johnson ML (2004) The high bone mass family–the role of Wnt/Lrp5 signaling in the regulation of bone mass. J Musculoskelet Neuronal Interact 4(2):135–138PubMed Johnson ML (2004) The high bone mass family–the role of Wnt/Lrp5 signaling in the regulation of bone mass. J Musculoskelet Neuronal Interact 4(2):135–138PubMed
3.
go back to reference Wang C, Zhang G, Gu M, Zhou Z, Cao X (2014) Polymorphism of the low-density lipoprotein receptor-related protein 5 gene and fracture risk. Int J Clin Exp Med 7(12):5097–5103PubMedPubMedCentral Wang C, Zhang G, Gu M, Zhou Z, Cao X (2014) Polymorphism of the low-density lipoprotein receptor-related protein 5 gene and fracture risk. Int J Clin Exp Med 7(12):5097–5103PubMedPubMedCentral
4.
go back to reference Baron R, Rawadi G (2007) Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 5(2):73–80CrossRefPubMed Baron R, Rawadi G (2007) Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 5(2):73–80CrossRefPubMed
5.
go back to reference Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860–869CrossRefPubMed Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860–869CrossRefPubMed
6.
go back to reference Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25(57):7469–7481CrossRefPubMed Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25(57):7469–7481CrossRefPubMed
7.
go back to reference Choi HY, Dieckmann M, Herz J, Niemeier A (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4(11):e7930CrossRefPubMedPubMedCentral Choi HY, Dieckmann M, Herz J, Niemeier A (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4(11):e7930CrossRefPubMedPubMedCentral
8.
go back to reference Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391(6665):357–362CrossRefPubMed Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391(6665):357–362CrossRefPubMed
9.
go back to reference Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP, Niehrs C, Izpisúa Belmonte JC, Westphal H (2001) Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 1(3):423–434CrossRefPubMed Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP, Niehrs C, Izpisúa Belmonte JC, Westphal H (2001) Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 1(3):423–434CrossRefPubMed
10.
go back to reference Daoussis D, Andonopoulos AP (2011) The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 41(2):170–177CrossRefPubMed Daoussis D, Andonopoulos AP (2011) The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 41(2):170–177CrossRefPubMed
11.
go back to reference Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494CrossRefPubMed Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494CrossRefPubMed
12.
go back to reference Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21(6):934–945CrossRefPubMed Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21(6):934–945CrossRefPubMed
13.
go back to reference Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39(4):754–766CrossRefPubMed Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39(4):754–766CrossRefPubMed
14.
go back to reference Yao GQ, Wu JJ, Troiano N, Insogna K (2011) Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 29(2):141–148CrossRefPubMed Yao GQ, Wu JJ, Troiano N, Insogna K (2011) Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 29(2):141–148CrossRefPubMed
15.
go back to reference MacDonald BT, Adamska M, Meisler MH (2004) Hypomorphic expression of Dkk1 in the doublebridge mouse: dose dependence and compensatory interactions with Lrp6. Development 131(11):2542–2552CrossRef MacDonald BT, Adamska M, Meisler MH (2004) Hypomorphic expression of Dkk1 in the doublebridge mouse: dose dependence and compensatory interactions with Lrp6. Development 131(11):2542–2552CrossRef
16.
go back to reference MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV (2007) Bone mass is inversely proportional to Dkk1 levels in mice. Bone 41(3):331–339CrossRefPubMedPubMedCentral MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV (2007) Bone mass is inversely proportional to Dkk1 levels in mice. Bone 41(3):331–339CrossRefPubMedPubMedCentral
17.
go back to reference Lewis SL, Khoo PL, De Young RA, Steiner K, Wilcock C, Mukhopadhyay M, Westphal H, Jamieson RV, Robb L, Tam PP (2008) Dkk1 and Wnt3 interact to control head morphogenesis in the mouse. Development 135(10):1791–1801CrossRefPubMed Lewis SL, Khoo PL, De Young RA, Steiner K, Wilcock C, Mukhopadhyay M, Westphal H, Jamieson RV, Robb L, Tam PP (2008) Dkk1 and Wnt3 interact to control head morphogenesis in the mouse. Development 135(10):1791–1801CrossRefPubMed
18.
go back to reference Fossat N, Jones V, Garcia-Garcia MJ, Tam PP (2012) Modulation of WNT signaling activity is key to the formation of the embryonic head. Cell Cycle 11(1):26–32CrossRefPubMed Fossat N, Jones V, Garcia-Garcia MJ, Tam PP (2012) Modulation of WNT signaling activity is key to the formation of the embryonic head. Cell Cycle 11(1):26–32CrossRefPubMed
19.
go back to reference Liu P, Wakamiya M, Shea MJ, Albrecht U, Behringer RR, Bradley A (1999) Requirement for Wnt3 in vertebrate axis formation. Nat Genet 22(4):361–365CrossRefPubMed Liu P, Wakamiya M, Shea MJ, Albrecht U, Behringer RR, Bradley A (1999) Requirement for Wnt3 in vertebrate axis formation. Nat Genet 22(4):361–365CrossRefPubMed
20.
go back to reference Koide M, Kobayashi Y, Yamashita T, Uehara S, Nakamura M, Hiraoka BY, Ozaki Y, Iimura T, Yasuda H, Takahashi N, Udagawa N (2017) Bone formation is coupled to resorption via suppression of sclerostin expression by osteoclasts. J Bone Miner Res. doi:10.1002/jbmr.3175 PubMed Koide M, Kobayashi Y, Yamashita T, Uehara S, Nakamura M, Hiraoka BY, Ozaki Y, Iimura T, Yasuda H, Takahashi N, Udagawa N (2017) Bone formation is coupled to resorption via suppression of sclerostin expression by osteoclasts. J Bone Miner Res. doi:10.​1002/​jbmr.​3175 PubMed
21.
go back to reference Mo XB, Lu X, Zhang YH, Zhang ZL, Deng FY, Lei SF (2015) Gene-based association analysis identified novel genes associated with bone mineral density. PLoS ONE 10(3):e0121811CrossRefPubMedPubMedCentral Mo XB, Lu X, Zhang YH, Zhang ZL, Deng FY, Lei SF (2015) Gene-based association analysis identified novel genes associated with bone mineral density. PLoS ONE 10(3):e0121811CrossRefPubMedPubMedCentral
22.
go back to reference Zhou F, Meng S, Song H, Claret FX (2013) Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev 27(6):261–267CrossRefPubMedPubMedCentral Zhou F, Meng S, Song H, Claret FX (2013) Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Rev 27(6):261–267CrossRefPubMedPubMedCentral
23.
go back to reference Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2):371–379CrossRefPubMedPubMedCentral Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2):371–379CrossRefPubMedPubMedCentral
24.
go back to reference Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24(3):425–436CrossRefPubMed Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24(3):425–436CrossRefPubMed
25.
go back to reference Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E (2006) Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Politou Int J Cancer. 119(7):1728–1731CrossRefPubMed Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E (2006) Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Politou Int J Cancer. 119(7):1728–1731CrossRefPubMed
26.
go back to reference Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC (2014) A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167(3):366–375CrossRefPubMed Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC (2014) A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167(3):366–375CrossRefPubMed
27.
go back to reference Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747–783CrossRefPubMed Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747–783CrossRefPubMed
28.
go back to reference Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, Zhang L, Han CY, Case R, Duguay AN, Grisanti M, Stevens J, Pretorius JK, Pacheco E, Jones H, Chen Q, Soriano BD, Wen J, Heron B, Jacobsen FW, Brisan E, Richards WG, Ke HZ, Ominsky MS (2016) A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun 7:11505CrossRefPubMedPubMedCentral Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, Zhang L, Han CY, Case R, Duguay AN, Grisanti M, Stevens J, Pretorius JK, Pacheco E, Jones H, Chen Q, Soriano BD, Wen J, Heron B, Jacobsen FW, Brisan E, Richards WG, Ke HZ, Ominsky MS (2016) A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun 7:11505CrossRefPubMedPubMedCentral
29.
go back to reference Salinas PC, Fletcher C, Copeland NG, Jenkins NA, Nusse R (1994) Maintenance of Wnt-3 expression in Purkinje cells of the mouse cerebellum depends on interactions with granule cells. Development 120(5):1277–1286PubMed Salinas PC, Fletcher C, Copeland NG, Jenkins NA, Nusse R (1994) Maintenance of Wnt-3 expression in Purkinje cells of the mouse cerebellum depends on interactions with granule cells. Development 120(5):1277–1286PubMed
30.
go back to reference Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L et al (2010) Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 285(51):40135–40147CrossRefPubMedPubMedCentral Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L et al (2010) Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 285(51):40135–40147CrossRefPubMedPubMedCentral
31.
go back to reference Tai N, Inoue D (2014) New development in osteoporosis treatment. Anti-Dickkopf1 (Dkk1) antibody as a bone anabolic agent for the treatment of osteoporosis. Clin Calcium 24(1):75–83PubMed Tai N, Inoue D (2014) New development in osteoporosis treatment. Anti-Dickkopf1 (Dkk1) antibody as a bone anabolic agent for the treatment of osteoporosis. Clin Calcium 24(1):75–83PubMed
Metadata
Title
Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation
Authors
Michelle M. McDonald
Alyson Morse
Aaron Schindeler
Kathy Mikulec
Lauren Peacock
Tegan Cheng
Justin Bobyn
Lucinda Lee
Paul A. Baldock
Peter I. Croucher
Patrick P. L. Tam
David G. Little
Publication date
01-01-2018
Publisher
Springer US
Published in
Calcified Tissue International / Issue 1/2018
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-017-0338-4

Other articles of this Issue 1/2018

Calcified Tissue International 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.